Top Page
Krystal Biotech
(NASDAQ:KRYS)
Krystal Biotech (KRYS) vs. SPDR S&P 500 ETF (SPY)
Krystal Biotech Business Overview & Revenue Model
Krystal Biotech Earnings Call Summary
Krystal Biotech Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 359.20M | 290.51M | 50.70M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 333.84M | 270.45M | 47.60M | -4.05M | -2.77M | -1.85M |
| EBITDA | 151.31M | 109.91M | 17.90M | -145.20M | -65.31M | -30.32M |
| Net Income | 146.72M | 89.16M | 10.93M | -139.97M | -69.57M | -32.17M |
Balance Sheet | ||||||
| Total Assets | 1.14B | 1.06B | 818.36M | 558.45M | 626.29M | 310.84M |
| Cash, Cash Equivalents and Short-Term Investments | 681.99M | 597.52M | 532.18M | 379.17M | 438.10M | 271.26M |
| Total Debt | 1.62M | 7.26M | 8.09M | 8.93M | 8.02M | 11.55M |
| Total Liabilities | 97.75M | 109.46M | 39.71M | 36.22M | 32.72M | 18.76M |
| Stockholders Equity | 1.04B | 946.38M | 778.64M | 522.23M | 593.58M | 292.08M |
Cash Flow | ||||||
| Free Cash Flow | 185.44M | 119.18M | -100.60M | -153.55M | -116.27M | -40.93M |
| Operating Cash Flow | 195.40M | 123.42M | -88.80M | -100.57M | -47.94M | -26.08M |
| Investing Cash Flow | -183.40M | -163.44M | 82.64M | -114.08M | -226.77M | -11.18M |
| Financing Cash Flow | -4.88M | 27.01M | 202.75M | 35.35M | 347.69M | 118.02M |
Krystal Biotech Technical Analysis
Krystal Biotech Risk Analysis
Krystal Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $3.98B | 27.98 | 15.61% | ― | 116.09% | 35.29% | |
68 Neutral | $9.05B | ― | -36.38% | ― | ― | 34.29% | |
54 Neutral | $1.75B | 19.61 | -4.76% | ― | 64.89% | -221.56% | |
53 Neutral | $5.19B | ― | -280.68% | ― | 69.83% | 22.16% | |
47 Neutral | C$212.69M | -2.68 | -24.76% | 3.10% | 19.76% | 0.48% | |
46 Neutral | $3.98B | ― | 435.49% | ― | 2635.74% | 4.66% |
Krystal Biotech Corporate Events
On July 24, 2025, Japan’s Ministry of Health, Labour and Welfare approved VYJUVEK® for treating dystrophic epidermolysis bullosa (DEB), marking it as the first genetic medicine for DEB in Japan. This approval allows flexible administration, including home dosing, and is based on a comprehensive clinical dataset showing positive outcomes. The approval is a significant milestone for Krystal Biotech, positioning them as a leader in genetic medicine for DEB and expanding their market presence in Japan, with commercial launch expected by the end of the year.
The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.
On July 24, 2025, Jeune Aesthetics, a subsidiary of Krystal Biotech, announced positive results from a Phase 1 study of KB304 for treating wrinkles of the décolleté. The study showed significant improvements in skin attributes such as wrinkles and elasticity, with KB304 outperforming placebo. The company plans to advance KB304 to Phase 2 development, aiming to fill a market gap for FDA-approved injectables in this area.
The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.
On July 9, 2025, Krystal Biotech announced the dosing of the first patient in its Phase 1/2 trial of KB801, a gene therapy eye drop for neurotrophic keratitis (NK), a degenerative corneal disease. The trial, named EMERALD-1, aims to evaluate the safety and efficacy of KB801, which promises to reduce treatment burden by enabling sustained expression of nerve growth factor in the eye. The company also hosted a conference call and webcast to discuss the trial and its implications, highlighting the potential of KB801 to address the unmet needs of NK patients.
The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.
On June 2, 2025, Krystal Biotech presented a clinical update on its Phase 1/2 trial of inhaled KB707, a novel HSV-based immunotherapy for advanced lung tumors, at the ASCO Annual Meeting. The study showed that KB707 was safe, well-tolerated, and demonstrated promising anti-tumor effects, with a 36% objective response rate in heavily pre-treated non-small cell lung cancer patients. The results suggest potential synergy with immune checkpoint inhibitors, and further evaluation is ongoing.
The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.
On May 16, 2025, Krystal Biotech held its Annual Meeting of Stockholders where key decisions were made, including the election of Class II directors and the ratification of KPMG LLP as the independent registered public accounting firm for 2025. Additionally, stockholders approved the compensation of the company’s named executive officers for the fiscal year 2024, reflecting confidence in the company’s leadership and strategic direction.
The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.
On May 9, 2025, Krystal Biotech presented a poster at the Society for Investigative Dermatology Annual Meeting, detailing the expansion of its HSV-1-based gene therapy platform to treat Hailey-Hailey and Darier diseases. The studies demonstrated that the company’s gene therapy vectors, KB111 and KB112, can effectively transduce keratinocytes and express ATPases with minimal toxicity, indicating promising potential for treating these rare skin conditions.
The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.